Ethyl Acetate

Ethyl Acetate

SCHEMBL756143

CCCCCCCC(=O)OCC.CCOC(C)=O

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DGKA P23743 1/20 0.64
PAM P19021 2/20 0.58
LMNA P02545 5/20 0.56
ALDH1A1 P00352 2/20 0.56
HSD17B10 Q99714 1/20 0.56
TSHR P16473 1/20 0.55
MAPT P10636 1/20 0.55
PRKCA P17252 3/20 0.54
CYP1A2 P05177 1/20 0.53
DNM1 Q05193 1/20 0.53
KDM4E B2RXH2 1/20 0.51
DUSP3 P51452 1/20 0.51
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
PRKCE Q02156 1/20 0.49
PRKCQ Q04759 1/20 0.49
PRKCD Q05655 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethyl Acetate SCHEMBL1614072 1.00 DGKA (0.64) DGKAPAMLMNAALDH1A1HSD17B10
Hexane SCHEMBL19611429 1.00 DGKA (0.64) DGKAPAMLMNAALDH1A1HSD17B10
Ethyl Acetate SCHEMBL1777438 1.00 DGKA (0.64) DGKAPAMLMNAALDH1A1HSD17B10
Ethyl Acetate SCHEMBL31373773 1.00 DGKA (0.64) DGKAPAMLMNAALDH1A1HSD17B10
Ethyl Acetate SCHEMBL11889416 0.98 DGKA (0.62) DGKAPAMLMNAALDH1A1HSD17B10
Ethyl Acetate SCHEMBL27394742 0.98 DGKA (0.61) DGKAPAMLMNAALDH1A1HSD17B10
Ethyl Acetate SCHEMBL3483756 0.93 DGKA (0.56) DGKAPAMLMNAALDH1A1HSD17B10
Ethyl Acetate SCHEMBL4168022 0.93 DGKA (0.56) DGKAPAMLMNAALDH1A1HSD17B10
Ethyl Acetate SCHEMBL3310609 0.93 DGKA (0.56) DGKAPAMLMNAALDH1A1HSD17B10
Acetone SCHEMBL1868300 0.92 DGKA (0.69) DGKAPAMLMNAALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 230 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240092784-A1 CONDENSED HETEROCYCLIC COMPOUND NISSAN CHEMICAL CORPORATION (JP) 2024-03-21 US disclosed
CN-117529547-A Novel polymer coating crosslinked alginic acid gel fiber 持田制药株式会社 2024-02-06 CN disclosed
CN-116710110-A Novel multi-layer polymer coating crosslinked alginic acid gel fiber 持田制药株式会社 2023-09-05 CN disclosed
EP-4219500-A1 CONDENSED HETEROCYCLIC COMPOUND Nissan Chemical Corporation (JP) 2023-08-02 EP disclosed
EP-1939204-B3 FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF KISSEI PHARMACEUTICAL (JP) 2022-08-24 EP disclosed
US-20200297700-A1 BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF TOBIRA THERAPEUTICS INC (US) 2020-09-24 US disclosed
CN-105801489-B Cycloalkyl-substituted imidazole derivatives 第一三共株式会社 2019-12-10 CN disclosed
CN-104640847-B Novel Renin Inhibitors 上海医药集团股份有限公司 2019-10-15 CN disclosed
US-10287313-B2 RNA monomers containing 0-acetal levulinyl ester groups and their use in RNA microarrays THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2019-05-14 US disclosed
US-10155731-B2 Nitrogen-containing saturated heterocyclic compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2018-12-18 US disclosed
EP-0624584-A1 Piperazine derivatives useful as calmodolin inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1994-11-17 EP disclosed
US-5354872-A Process for preparation of calcitriol lactone and related intermediates ALCON LABORATORIES, INC. (US) 1994-10-11 US disclosed
CN-1061971-A Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and angiotensin converting enzyme MERRELL DOW PHARMA (US) 1992-06-17 CN disclosed
US-5095013-A Antibiotics BANYU PHARMACEUTICAL CO., LTD. (JP) 1992-03-10 US disclosed
EP-0411664-A2 2-(2-Vinylpyrrolidinylthio)carbapenem derivatives Banyu Pharmaceutical Co., Ltd. (JP) 1991-02-06 EP disclosed
EP-0361772-A2 Cyclopentyl ethers and their preparation and pharmaceutical formulation GLAXO GROUP LIMITED (GB) 1990-04-04 EP disclosed
EP-0125052-B1 DOPAMINERGIC CARBOSTYRILS AND A PROCESS FOR PREPARING THEM SMITHKLINE BECKMAN CORPORATION (US) 1988-01-27 EP disclosed
EP-0125052-A2 Dopaminergic carbostyrils and a process for preparing them SMITHKLINE BECKMAN CORPORATION (US) 1984-11-14 EP disclosed
EP-0000833-B1 DERIVATIVES OF PHOSPHONOACYL PROLINES AND THEIR PHARMACEUTICAL USE E.R. Squibb & Sons, Inc. (US) 1981-09-02 EP disclosed
EP-0000833-A1 Derivatives of phosphonoacyl prolines and their pharmaceutical use E.R. Squibb & Sons, Inc. (US) 1979-02-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10287313-B2 RNA monomers containing 0-acetal levulinyl ester groups and their use in RNA microarrays EFTUD2, RNMT, NSUN2 DGKA 3698/4885PAM 918/4885LMNA 565/4885
US-10155731-B2 Nitrogen-containing saturated heterocyclic compound REN, AGTR1, AGTR2 DGKA 4829/4885PAM 1205/4885LMNA 2965/4885
US-20240092784-A1 CONDENSED HETEROCYCLIC COMPOUND SPR, QDPR, SUCNR1 DGKA 4694/4885PAM 1966/4885LMNA 2911/4885
US-20200297700-A1 BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF CCR5, CCR1, CCR2 DGKA 4554/4885PAM 1857/4885LMNA 4285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.